However, the prognosis achieved with cCRT remains un-satisfactory with the 5-year overall survival (OS) rate of 15%.2 Recently, a randomised controlled trial demonstrated that the consolidation treatment with durvalumab, an antibody against programmed death ligand-1 (PD-L1), provided a significant survival benefit among patients who did not have disease progression after cCRT.3,4 Based on the results, durvalumab treatment following cCRT has become a new standard of care for locally advanced and unresectable NSCLC patients with good performance status (PS).5 This evidence concerns the gene CD274 and non-small cell lung carcinoma.